A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
To estimate the antitumor efficacy of CI-958 in patients with measurable recurrences of platinum-sensitive ovarian carcinoma and to determine the nature and degree of toxicity of CI-958 in these patients. Patients received CI-958 560 mg/m2 intravenously every 3 weeks and tumor measurements were performed every one to two cycles. Of 23 patients entered in the study, there was one complete response and 10 patients had stable disease with short response durations. CI-958 has minimal activity in recurrent platinum-sensitive ovarian carcinoma at the dose and schedule tested.